VASCULOGENIC · NEUROGENIC · POST-PROSTATECTOMY · DIABETIC · AGE-RELATED
A physician-led, laboratory-verified regenerative programme that addresses the underlying biology of erectile dysfunction — endothelial damage, cavernosal microcirculation, neurovascular signalling, chronic low-grade inflammation and fibrotic remodelling — rather than only the vasodilatory symptom.
Request Medical ConsultationAbout the Condition
Erectile dysfunction (ED) is driven by endothelial damage, cavernosal microvascular insufficiency, impaired neurovascular signalling, oxidative stress and chronic low-grade inflammation. PDE5 inhibitors deliver only on-demand vasodilation — they do not repair the underlying tissue.
Our regenerative protocol acts on the upstream biology — Tregs (CD4+CD25+FOXP3+), mesenchymal stem cells and concentrated exosomes — to restore endothelial function, drive neoangiogenesis, support neural regeneration and suppress cavernosal fibrosis.
Vasculogenic ED
Caused by impaired arterial inflow and endothelial dysfunction of the cavernosal arteries. Often coexists with cardiovascular disease, hypertension, dyslipidaemia and metabolic syndrome. Accounts for approximately 60–70% of organic ED cases.
Neurogenic ED
Develops after damage to the cavernous nerves or pelvic autonomic plexus — most commonly following radical prostatectomy, pelvic surgery, spinal cord injury or in the context of diabetic autonomic neuropathy. Requires a regenerative approach targeting neural pathways, not vasodilation alone.
Diabetic ED
Multifactorial form combining endothelial dysfunction, microvascular damage, autonomic neuropathy and chronic inflammation driven by hyperglycaemia. Tends to be more refractory to PDE5 inhibitors and benefits most from a combined immunomodulatory and regenerative protocol.
Post-Prostatectomy ED
Occurs after radical prostatectomy due to neurovascular bundle injury and subsequent cavernosal fibrosis. Targeted local therapy with neural-trophic factors and antifibrotic mediators can support recovery of erectile function in selected patients.
Age-Related & Endothelial ED
Linked to progressive endothelial senescence, reduced eNOS activity, lower NO bioavailability and accumulated oxidative damage. Responds well to a programme combining endothelial repair, mitochondrial support and immune rebalancing.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, including cardiovascular evaluation, endocrine and metabolic profiling, vascular imaging where indicated and review of contributing comorbidities.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
68%
measurable improvement on IIEF-5 at 3–6 months
+6.4 pts
average IIEF-5 score gain at 6 months vs. baseline
61%
sustained functional improvement with average 18 months of follow-up
72%
showed improvement in penile Doppler peak systolic velocity
54%
reduced dependence on or discontinued PDE5 inhibitors at 12 months
Erectile function (IIEF-5 score, EHS hardness scale)
68%
Endothelial / vascular response (penile Doppler peak systolic velocity, end-diastolic velocity)
64%
Neurovascular / autonomic signalling (response to tactile and visual stimulation)
58%
Quality of life and partner-reported outcome (SEAR, partner questionnaire)
70%
3–6 weeks
Initial vascular response
2–4 months
Clinically meaningful change in IIEF-5
12 months onward
Long-term stability — continuous monitoring
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationThe BioCells Program
Our erectile dysfunction programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's vascular status, neural integrity, metabolic profile, hormonal balance and clinical priorities.
Minimally invasive administration
Treatment is delivered by intravenous infusion or targeted local injection — not surgical instruments. No incisions, no implants.
No general anaesthesia
All procedures are performed under local anaesthesia or without anaesthesia at all. Important for patients with cardiovascular comorbidities.
No risk of immune rejection
MSCs are immunoprivileged: they express low levels of HLA-I, lack HLA-II and carry a minimal risk of rejection whether the protocol is autologous or allogeneic. Allogeneic MSC protocols do not require immunosuppression.
Targets the underlying biology, not just vasodilation
Rather than triggering on-demand blood flow, our protocol addresses endothelial damage, cavernosal microvascular insufficiency, fibrosis and neural compromise — the upstream biology that drives ED in the first place.
Complements existing therapy
Our programme is compatible with PDE5 inhibitors, testosterone replacement therapy and cardiovascular medication. Patients do not need to discontinue existing treatment before commencing our protocol.
Patients from around the world
We work with patients from around the world. Airport transfers, accommodation, visa support and multilingual coordination are included in every treatment programme.
What It Is
MSCs are multipotent regenerative cells with established angiogenic, neurotrophic and antifibrotic properties. They are among the most extensively studied cell types in regenerative medicine for endothelial and neurovascular repair.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 3–5 ml under local anaesthesia) or sourced from certified donor tissue (allogeneic), depending on individual clinical indications. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Erectile Dysfunction
In ED, the central biological lesion is loss of functional cavernosal microvasculature, impaired endothelial signalling and progressive smooth muscle fibrosis. MSCs address all three simultaneously — releasing growth factors that rebuild capillary networks, restoring endothelial function and suppressing the TGF-β driven fibrosis that converts erectile smooth muscle into scar tissue.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your ED subtype, vascular and neural assessment, metabolic and hormonal status and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your medical history, ED subtype, response to previous therapy and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation — urology reports, penile Doppler ultrasound where available, metabolic and hormonal panel and cardiovascular assessment. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion and, where indicated, by targeted local intracavernosal administration — no surgery, no general anaesthesia. Airport transfers, accommodation and visa support are included in the programme for international patients.
Structured rehabilitation sessions with our specialist, including pelvic floor and cardiovascular conditioning, neurostimulation and shockwave support where indicated, and lifestyle optimisation. Available at our clinic or remotely coordinated with your local urologist.
Your dedicated coordinator monitors erectile function (IIEF-5, EHS), vascular response and metabolic status. A medical-grade wearable bracelet supports continuous physiological monitoring regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of ED patients.
Temporary mild reactions — such as transient local discomfort at the infusion or injection site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and reflect normal biological engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including new cardiovascular events or active infection — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac, renal or hepatic failure
Untreated severe penile deformity (Peyronie's plaque under acute inflammatory phase) — requires individual assessment
Post-Treatment
Dedicated urology-trained coordinator
monitors erectile function, vascular response and metabolic markers
Personalised rehabilitation programme
including pelvic floor work, cardiovascular conditioning and lifestyle optimisation
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and protocol reassessment at defined intervals
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Vascular and neural regeneration is a gradual biological process. Cavernosal tissue that has been under metabolic, inflammatory or surgical stress for years does not recover in weeks. The post-treatment period requires structured monitoring, periodic reassessment and — where indicated — protocol adjustment based on evolving clinical data.
Patient Stories
“I had been on tadalafil daily for three years after my prostatectomy and the response was steadily fading. After the programme my spontaneous response gradually returned over about four months. I no longer take the daily dose. It is not what I had at 30, but the quality of life difference is enormous.”
Patient
Post-prostatectomy ED · Germany
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationPatient Cases
Documented treatment outcomes recorded by the BioCells Medical team after personalised regenerative medicine protocols.
Get Started
If you have been living with erectile dysfunction that no longer responds to standard treatment, our medical team is available for a free, no-obligation medical consultation — based on your medical history, ED subtype and individual clinical profile.
We review every inquiry personally and confidentially. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
